Laurie Barclay, MD
NEW YORK (MedscapeWire) Mar 26 US Food and Drug Administration (FDA) investigators describe 5 cases of aseptic meningitis caused by rofecoxib in the March 25 issue of the Archives of Internal Medicine.
"As with other [nonsteroidal anti-inflammatory drugs (NSAIDs)], rofecoxib should be considered in the differential diagnosis of aseptic meningitis with or without rheumatological disease," write Renan A. Bonnel, PharmD, MPH, and colleagues from the FDA.
Although aseptic meningitis is known to be a rare adverse effect of NSAIDs, this is the first published series implicating the new cyclooxygenase (COX)-2 inhibitors.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!